Search

Dr. Brunoni's research focuses on developing innovative therapeutic strategies using transcranial direct current stimulation, transcranial magnetic stimulation, and other neuromodulation techniques for treating major depressive disorder, bipolar disorder, OCD, schizophrenia, and post-COVID cognitive symptoms.

Meet our Principal Investigator, Christian LoBue, Ph.D. 

The Cardiovascular Pharmacotherapy Research Lab integrates molecular epidemiology, clinical pharmacology, clinical trials and population health science to identify new pathways and therapeutic strategies for the prevention of heart failure. Our team conducts cross-disciplinary, mechanism-focused clinical research to translate biologic discoveries into interventions with meaningful public health impact.

The research interests of the Lux Lab lie in the development of novel nanomedicine platforms to diagnose and treat disease in vivo noninvasively.

Contact information for the Nair-Gill Lab

Our group initially investigated a novel immune checkpoint inhibitor targeting a rare heparan sulfate (rHS) in melanoma treatment. Collaboratively, we explored the potential of a single-domain humanized rHS antibody (1A7 clone) that inhibits DC-HIL function and also angiogenesis and chemokine effects linked to diverse cancer progression signaling pathways. This experience provided insights into rHS-targeting as a promising approach to melanoma therapy.

Our goal is to track the signaling dynamics of individual effectors and toxins in living cells, using a combination of fluorescent genetic reporters, microinjection of labeled bacterial proteins, and live cell imaging techniques. 

We do difficult experiments at the frontier of cell physiology, often with our own methods and always with our own hands.

Multidisciplinary research to beat cancer

In the Zhang Lab, we seek to understand the molecular mechanisms of metabolic diseases, with the long-term goal of creating novel therapeutic strategies.